Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor

Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor

Multidrug resistance (MDR) is the main cause of clinical treatment failure and poor prognosis in cancer. Targeting P-glycoprotein (P-gp) has been regarded as an effective strategy to overcome MDR. In this work, we reported our preclinical studies of the triazolo[1,5-a]pyrimidine-based compound WS-71...

Full description

Bibliographic Details
Main Authors: Sai-Qi Wang, Qiu-Xu Teng, Shuai Wang, Zi-Ning Lei, Hui-Hui Hu, Hui-Fang Lv, Bei-Bei Chen, Jian-Zheng Wang, Xiao-Jing Shi, Wei-Feng Xu, Hong-Min Liu, Xiao-Bing Chen, Zhe-Sheng Chen, Bin Yu
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Multidrug resistance (MDR)
ATP-Binding cassette
P-gp inhibitors
Triazolo[1,5-a]pyrimidine
Drug combination
Preclinical studies
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522001538

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522001538

Similar Items